email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
826 - 840
of 3630 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
Next
Full-Life Closes $37 Million Series A for Radiopharmaceutical Oncology Products
$5.00
Available
Laekna Starts China-US Trials of AKT Kinase Inhibitor for Breast Cancer
$5.00
Available
Junshi’s Novel SARS-CoV-2 Therapy Out-Performs Pfizer’s Paxlovid
$5.00
Available
DongCheng Acquires Imaging Tracer to Predict Immunotherapy Efficacy
$5.00
Available
CASI Signs $10 Million Out-licensing of CD38 for Autoimmune Indications to Tianshi
$5.00
Available
CanSino One-Shot COVID Vaccine Accepted by WHO
$5.00
Available
Fosun Acquires Novel Cancer Immunotherapy in $125 Million Deal
$5.00
Available
CTTQ Acquires Global Rights to Clinical Stage Symphogen Immunotherapy
$5.00
Available
Belief BioMed Reports Positive Data for Hemophilia Gene Therapy
$5.00
Available
Inmagene Approved to Start Phase I Trial of Novel BTK Inhibitor
$5.00
Available
Bayer/Merck Cardiovascular Drug Approved for China Use
$5.00
Available
Ascentage Oncology Drug Effective in Preclinical Tests for COVID Cytokine Storm
$5.00
Available
Hengrui Launches Luzsana to Bring its Novel Medications to Global Markets
$5.00
Available
Laekna Raises $61 Million for its 14-Drug Cancer/Liver Disease Portfolio
$5.00
Available
Kelun Out-Licenses Global Rights for Candidate to Merck/MSD in $1.4 Billion Deal
$5.00
Available